Needham Reiterates Buy on Revolution Medicines, Maintains $61 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Revolution Medicines (NASDAQ:RVMD) and maintained a price target of $61.
October 28, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Revolution Medicines and maintained a price target of $61, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $61 price target by Needham suggests a positive outlook for Revolution Medicines. This could lead to increased investor confidence and potentially a rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100